Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients

@article{Bachert2009ComparisonOT,
  title={Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients},
  author={Claus Bachert and Piotr Kuna and F Sanquer and Pablo Ivan and Vassil Dimitrov and M. M. Gorina and P.H. Van de Heyning and Andr{\'e}ia A. Loureiro},
  journal={Allergy},
  year={2009},
  volume={64}
}
Background:  Bilastine is a novel, nonsedating H1‐antihistamine developed for symptomatic treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria. The objective of this study was to compare the efficacy and safety of bilastine 20 mg vs placebo and desloratadine 5 mg in subjects with seasonal allergic rhinitis (SAR). 

Original article Efficacy and safety of bilastine 20mg compared with cetirizine 10mg and placebo in the treatment of perennial allergic rhinitis

Bilastine is a non-sedating second-generation H1 antihistamine with proven efficacy and safety in the treatment of patients with seasonal allergic rhinitis and urticaria and is demonstrated to be effective and safe in patients with perennial allergicrhinitis.

Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study

  • P. KunaC. Bachert R. Valiente
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2009
Background Bilastine is a new non‐sedative H1 receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).

Bilastine: a guide to its use in the treatment of symptomatic allergic rhinoconjunctivitis and urticaria

Bilastine is a new antihistamine indicated for the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria, with an overall tolerability profile similar to that of placebo.

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi‐centre, double‐blind, randomized, placebo‐controlled study

To cite this article: Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antépara I, Jáuregui I, Valiente R, the Bilastine International Working Group. Comparison of the efficacy and safety

How bilastine is used to treat allergic rhinitis and urticaria in children.

Evidence is reviewed for use of bilastine in children with allergic rhinoconjunctivitis or urticaria and several cases are presented which demonstrate its role in routine clinical practice.

Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis

A post-hoc analysis indicated that bilastine and cetirizine were similarly effective and more effective than placebo during a 4-week treatment period in patients with PAR and was shown to be safe and well-tolerated over a 1-year treatment period.

Bilastine in symptomatic allergic rhinoconjunctivitis and urticaria: a guide to its use

Bilastine has a favourable pharmacological profile, with a rapid onset of action and sustained efficacy over the 24-h dosing interval period, as well as a lack of CNS and cardiotoxic effects and clinically relevant drug interactions.

Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases

The safety and tolerability of bilastine 10 mg in children with allergic rhinoconjunctivitis and chronic urticaria is assessed.

Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine

  • R.B. LocksK. SantosJ. Silva
  • Medicine, Psychology
    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • 2017
The aim of this study was to determine whether there were differences in health‐related quality of life of patients with allergic rhinitis treated with bilastine 20 mg compared to those treated with

An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria

Clinical studies in allergic rhinitis and chronic urticaria show that once-daily treatment with bilastine 20 mg is effective in managing symptoms and improving patient’s quality of life, with at least comparable efficacy to other nonsedative H1-antihistamines.
...

References

SHOWING 1-10 OF 44 REFERENCES

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis

  • van CAUWENBERGEJuniper
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2000
This multinational, double‐blind, randomized, placebo‐controlled, parallel group study compared the efficacy, safety and impact on quality of life in seasonal allergic rhinitis patients (SAR) of fexofenadine and loratadine, when administered once daily.

Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic Rhinitis

Desloratadine 5mg once daily was effective and well tolerated in the treatment of symptoms associated with SAR following the first dose of therapy and continuing for the 2-week duration of the study during both the spring and fall allergy seasons.

The pharmacologic profile of desloratadine: a review

  • B. Henz
  • Medicine, Biology
    Allergy
  • 2001
Desloratadine had no effects on the corrected QT interval (QTc) when administered alone, at high dose, or in combination with ketoconazole or erythromycin, and preclinical studies show that deslor atadine does not interfere with HERG channels or cardiac conduction parameters even at high doses.

Desloratadine in the Treatment of Seasonal Allergic Rhinitis

This study supports the evidence from placebo-controlled trials that desloratadine is an effective and well tolerated treatment for SAR symptoms, including nasal congestion.

Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium

This data indicates that vaccination against noninfectious, nonallergic rhinitis and NINA is a viable treatment option for AR and may help reduce the number of patients seeking medical help.

Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Among the antihistamines presently available, fexofenadine may offer the best overall balance of effectiveness and safety, and this agent is an appropriate selection for initial or switch therapy for most patients with mild or moderate allergic symptoms.

Classification and management of allergic rhinitis patients in general practice during pollen season

This study conducted this study to further characterize the classes of AR described by ARIA, and to evaluate whether the management of AR in general practice is in accordance with the ARIA guidelines.

Economic impact and quality-of-life burden of allergic rhinitis

It was concluded that greater awareness of the total economic burden of allergic rhinitis should encourage appropriate intervention and ultimately ensure clinically favorable and cost-effective outcomes.

Consensus statement * on the treatment of allergic rhinitis

Current guidelines emphasize the importance of an accurate diagnosis of patients presenting with rhinitis symptoms and the morbidity of SAR obviously depends on the geographic region, the pollen season of the plants, and the local climate.

In Vivo Pharmacological Characterisation of Bilastine, a Potent and Selective Histamine H1 Receptor Antagonist

In vivo preclinical studies corroborate those obtained from previously conducted in vitro experiments of bilastine, and provide evidence that bilastines possesses antihistaminic as well as antiallergic properties, with similar potency to cetirizine and superior potency to fexofenadine.